Essential thrombocythemia · 3 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Ruxolitinib monotherapy Variant #06 Partial | — | R 48 520 | — | — | — | ~1 | ~R 48 520 PFS proxy · indirect | 2 |
Anagrelide monotherapy Variant #01 | — | R 6 061 | 28d | — | — | ~2 | ~R 12 122 indirect | — |
Peginterferon alfa-2a monotherapy Variant #01 Partial | — | — | 7d | — | — | ~4 | — | — |
3 of 3 regimens shown